Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Fineline Cube Apr 30, 2026
Company Deals

Fosun Pharma and Arcera Life Sciences Forge Strategic Partnership to Bridge Chinese Biotech Innovation with Global Markets

Fineline Cube Apr 29, 2026
Company Deals

Hengrui Pharmaceuticals Partners with Sun Yat-sen University to Integrate Industry-Academia Innovation Ecosystem

Fineline Cube Apr 29, 2026
Company Deals

Vivacta Biotechnology Secures $50M+ Series A Financing to Advance In Vivo CAR-T Therapy GT801

Fineline Cube Apr 29, 2026
Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Fineline Cube Apr 30, 2026
Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Fineline Cube Apr 30, 2026
Company Deals

Smith & Nephew Partners with MedMotion for Digital Health Innovation

Fineline Cube Mar 22, 2023

UK-based Smith & Nephew Plc has announced a strategic partnership with China’s Shanghai Fudong Medical...

Company Deals

Aidea Pharma and China Meheco Partner to Expand Medical and Pharmaceutical Services

Fineline Cube Mar 22, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced a partnership with China Meheco...

Company

3SBio Inc. Reports 7.5% Revenue Growth in 2022 Financials

Fineline Cube Mar 22, 2023

China-based 3SBio Inc. (HKG: 1530) released its 2022 financial report, recording revenues of RMB 6.859...

Company Deals

Joincare Pharmaceutical Acquires Rights to TaiGen’s PA Endonuclease Inhibitor TG-1000

Fineline Cube Mar 22, 2023

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced a licensing agreement with...

Company Drug

Reistone Biopharma’s Ivarmacitinib Shows Positive Results in Phase III QUARTZ3 Study

Fineline Cube Mar 22, 2023

Reistone Biopharma Co., Ltd, incubated by Hengrui Pharmaceuticals (SHA: 600276) with USD 100 million in...

Company Deals

Sinopharm Forms Joint Ventures with Foreign Medical Equipment Firms

Fineline Cube Mar 22, 2023

Sinopharm China National Biotech Group Co., Ltd (CNBG) has announced partnerships with two foreign medical...

Company

BeiGene Marks Topping Off of New Biologics Facility in New Jersey

Fineline Cube Mar 22, 2023

China-based biotech BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) held a ceremony to mark the...

Company Deals Digital

Roche Partners with China Resource Medicine to Promote Xofluza in China

Fineline Cube Mar 22, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has entered into a partnership with China-based China Resource...

Company Deals

Jacobio Pharma Partners with Merck to Evaluate CD73 mAb and Keytruda Combination

Fineline Cube Mar 22, 2023

China-based Jacobio Pharma (HKG: 1167) has announced a clinical partnership with Merck, Sharp & Dohme...

Company Drug

Yifan Pharmaceutical’s F-652 Cleared for Phase II Trial in Alcoholic Hepatitis

Fineline Cube Mar 21, 2023

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced that its subsidiary Evive Biotech Ltd’s...

Company Deals

BioNTech Acquires Global Rights to OncoC4’s Anti-CTLA-4 Antibody ONC-392

Fineline Cube Mar 21, 2023

Germany-based mRNA specialist BioNTech SE (NASDAQ: BNTX) has unveiled a licensing deal and collaboration with...

Company Deals

Cygnus Bio Raises Millions in Series C+ Financing for Sequencing Technology

Fineline Cube Mar 21, 2023

Beijing-based second-generation sequencing technology platform Cygnus Bio has reportedly raised “hundreds of millions” of renminbi...

Company Deals

L&L Biopharma Completes Series B Financing for Tumor Immunotherapy Development

Fineline Cube Mar 21, 2023

Shanghai-based tumor immunotherapy developer L&L Biopharma Co., Ltd has announced the completion of a Series...

Company Deals

T&L Biotechnology Secures RMB 100 Million in Series A Financing

Fineline Cube Mar 21, 2023

Beijing-based cell and gene therapy (CGT) developer T&L Biotechnology Co., Ltd has reportedly raised RMB...

Company Drug

Yiling Pharmaceutical’s BIO-008 Receives NMPA Approval for Clinical Trials

Fineline Cube Mar 21, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...

Company Drug

Hengrui Pharmaceuticals’ SHR8028 Receives NMPA Review for Dry Eye Treatment

Fineline Cube Mar 21, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that a market approval filing...

Company Deals

LBX Pharmacy Partners with Gilead Sciences to Enhance Disease Management in China

Fineline Cube Mar 21, 2023

China-based LBX Pharmacy has entered into a partnership with US-based Gilead Sciences, Inc (NASDAQ: GILD)....

Company Drug

Jiangsu Recbio’s ReCOV Vaccine Receives Emergency Use Authorization in Mongolia

Fineline Cube Mar 21, 2023

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has announced that it has...

Company

WuXi AppTec Reports 71.8% Revenue Growth in 2022 Financials

Fineline Cube Mar 21, 2023

China-based WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) released its 2022 financial report, recording...

Company Drug

Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review

Fineline Cube Mar 21, 2023

China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its...

Posts pagination

1 … 541 542 543 … 659

Recent updates

  • Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate
  • Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength
  • Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026
  • Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China
  • Suzhou Basecare Medical Secures China’s First NMPA Approval for Thalassemia Preimplantation Genetic Testing Kit
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Allist Pharmaceuticals Secures China BTD for KRAS G12C NSCLC Combination Therapy with 71% Response Rate

Company

Regeneron Reports 19% Revenue Growth in Q1 2026 Driven by EYLEA HD Transition and Dupixent Collaboration Strength

Company Drug

Gilead’s Investigational HIV Regimen BIC/LEN Receives FDA Acceptance for Review with Decision Expected August 2026

Company Deals

Hengrui Pharmaceuticals Replaces Hansoh as Exclusive Licensee for KiOmed’s Osteoarthritis Drug in Greater China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.